| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/31/2002 | WO2002007705A1 Carrier material for dry powder inhalation |
| 01/31/2002 | WO2002007704A2 Improved process for manufacturing compositions containing ciprofloxacin and hydrocortisone |
| 01/31/2002 | WO2002007700A2 Compositions useful for regulating hair growth containing metal complexes of oxidized carbohydrates |
| 01/31/2002 | WO2002007685A2 Method of regulating hair growth using metal complexes of oxidized carbohydrates |
| 01/31/2002 | WO2002007683A1 Antimicotic nail varnish composition |
| 01/31/2002 | WO2002007682A1 Methods for treating atopic disorders |
| 01/31/2002 | WO2002007677A2 Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder |
| 01/31/2002 | WO2002007673A2 Calcilytic compounds |
| 01/31/2002 | WO2002007669A2 Phospholipid derivatives of valproic acid and mixtures thereof |
| 01/31/2002 | WO2002007624A1 Spinal implants, insertion instruments, and methods of use |
| 01/31/2002 | WO2002007623A1 Spine distraction implant |
| 01/31/2002 | WO2002007533A2 Nutritional composition |
| 01/31/2002 | WO2002007531A1 Dietary lipids for improving skin and coat of pets |
| 01/31/2002 | WO2002007520A2 Antimicrobial composition useful for the treatment of bovine mastitis |
| 01/31/2002 | WO2002007516A2 Uses for nad synthetase inhibitors |
| 01/31/2002 | WO2002007514A2 Glycosylated vegf-b and method for increasing the amount of soluble vegf-b |
| 01/31/2002 | WO2001081347A3 Diazabicyclic central nervous system active agents |
| 01/31/2002 | WO2001080873A3 Thrombopoietin receptor modulating peptide |
| 01/31/2002 | WO2001079158A3 Compounds for modulating cell proliferation |
| 01/31/2002 | WO2001078580A3 A method combining inducing hypothermia and administering a therapeutic agent |
| 01/31/2002 | WO2001070682A3 Carbocyclic side chain containing metalloprotease inhibitors |
| 01/31/2002 | WO2001070668A3 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 01/31/2002 | WO2001070172A3 Solid, water-dispersible, oral pharmaceutical form comprising rifampicin, isoniazid and pyridoxine hydrochloride, method for obtaining and presenting said pharmaceutical form |
| 01/31/2002 | WO2001068146A3 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| 01/31/2002 | WO2001066519A3 Method for preparing pyrimidone derivatives with antifungal activity |
| 01/31/2002 | WO2001064870A3 Mutated cyclin g1 protein |
| 01/31/2002 | WO2001062940A3 New phosphodiesterase type 7b |
| 01/31/2002 | WO2001062784A3 Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer |
| 01/31/2002 | WO2001062341A3 Combination product for the treatment of obesity |
| 01/31/2002 | WO2001061017A3 Modified cytokines for use in cancer therapy |
| 01/31/2002 | WO2001060832A3 Pluraflavins and derivatives thereof, process for their preparation and use thereof |
| 01/31/2002 | WO2001060348A3 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
| 01/31/2002 | WO2001058425A3 Pharmaceutical composition for pulmonary delivery |
| 01/31/2002 | WO2001054677A3 Ace inhibitor-vasopressin antagonist combinations |
| 01/31/2002 | WO2001043525A3 Method for the preparation of citalopram |
| 01/31/2002 | WO2001042457A3 Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s prnas and their uses |
| 01/31/2002 | WO2001039778A3 Triazinone compounds for treating diseases resulting from infestation with parasitic protozoans |
| 01/31/2002 | WO2001036605A3 2786, a human aminopeptidase |
| 01/31/2002 | WO2001034177A3 Method of treating a viral infection using antagonists of macrophage colony stimulating factor |
| 01/31/2002 | WO2001031343A3 Diagnosis and therapy of cancer using sgp28-related molecules |
| 01/31/2002 | WO2001030338A3 6-methoxy-2-naphthylacetic acid prodrugs for treating inflammation |
| 01/31/2002 | WO2001022791A3 Controlled release compositions comprising nimesulide |
| 01/31/2002 | WO2001021160A3 Carboxymide and aniline derivatives as selective inhibitors of pathogens |
| 01/31/2002 | WO2001008634A3 Polynucleotide encoding a human serine protease |
| 01/31/2002 | WO2000074700A3 Uses of ouabain and ouabain-like molecules in apoptosis related pathologies |
| 01/31/2002 | WO2000072836A3 Methods of promoting or enhancing interleukin-12 production through administration of thalidomide |
| 01/31/2002 | WO2000064487A8 Delivery of antimicrobial toxins |
| 01/31/2002 | WO2000057871A3 Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof |
| 01/31/2002 | WO2000034261A3 Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing a substituted phenylenediamine group |
| 01/31/2002 | US20020013662 Pharmacokinetic-based drug design tool and method |
| 01/31/2002 | US20020013496 Benzene compounds as antiproliferative and cholesterol lowering agents |
| 01/31/2002 | US20020013485 Cytotoxic agents comprising taxanes and their therapeutic use |
| 01/31/2002 | US20020013484 Water solubility; prodrug containing polyether oligomer |
| 01/31/2002 | US20020013481 Use of flavones flavanones and flavonoids for protecting ascorbic acid and/or ascorbyl compounds from oxidation |
| 01/31/2002 | US20020013476 Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| 01/31/2002 | US20020013469 Using thiazole derivative |
| 01/31/2002 | US20020013459 Process for the preparation of macrocyclic metalloprotease inhibitors |
| 01/31/2002 | US20020013374 Administering compound effective to inhibit binding of an amyloid beta peptide with alpha-7 nicotinic acetylcholine receptors |
| 01/31/2002 | US20020013373 Administering drug selected from D-propranolol, metoprolol, carvedilol, and bisoprolol and congeners and analogs, and metabolites thereof, to inhibit bronchorestriction in the human or animal for therapy of asthma |
| 01/31/2002 | US20020013371 Therapy of acute myelogenous leukemia in a human by administering arsenic trioxide |
| 01/31/2002 | US20020013370 Methods for identifying and treating resistant tumors |
| 01/31/2002 | US20020013369 Certain 5-alkyl-2arylaminophenylacetic acids and derivatives |
| 01/31/2002 | US20020013368 Methods and compositions for treating lipoxygenase-mediated disease states |
| 01/31/2002 | US20020013367 For therapy of neoplastic disease |
| 01/31/2002 | US20020013366 Methods of treating tardive dyskinesia and other movement disorders |
| 01/31/2002 | US20020013365 Conjugated linoleic acid powder |
| 01/31/2002 | US20020013364 Glycine site full agonist for treating a psychosis |
| 01/31/2002 | US20020013362 Used for administering paclitaxel to a patient with melanoma |
| 01/31/2002 | US20020013361 Treatment of rosacea using lipoic acid |
| 01/31/2002 | US20020013359 Pharmaceutical composition based on proline, glycine and lysine used in the therapy for the healing of tendon lesions and open wounds |
| 01/31/2002 | US20020013358 Indole derivatives |
| 01/31/2002 | US20020013357 Valdecoxib compositions |
| 01/31/2002 | US20020013356 New polycyclic indanylimidazoles with alpha2 adrenergic activity |
| 01/31/2002 | US20020013354 p38 map kinase inhibitors |
| 01/31/2002 | US20020013353 Blocking of associated non-inactivating sodium channels in retinal ganglion cells in order to limit sodium/calcium exchange in retinal ganglion cells and prevent buildup of calcium level in retinal ganglion cells to a lethal level |
| 01/31/2002 | US20020013352 Novel substituted diamine derivatives useful as motilin antagonists |
| 01/31/2002 | US20020013351 Compounds possessing neuronal activity |
| 01/31/2002 | US20020013349 Administering drug which opens potassium channel for reducing pain |
| 01/31/2002 | US20020013348 For prophylaxis and therapy of asthma, allergic rhinitis, dermatitis, conjunctivitis, atherosclerosis or rheumatoid arthritis, infection by HIV, delaying of the onset of AIDS |
| 01/31/2002 | US20020013347 Tri-aryl-substituted-ethane PDE4 inhibitors |
| 01/31/2002 | US20020013346 C7 ester substituted taxanes |
| 01/31/2002 | US20020013345 Treatment of diseases of the eye characterized by the formation of metalloproteinase |
| 01/31/2002 | US20020013344 Rotamas enzyme activity inhibitors |
| 01/31/2002 | US20020013343 Administering selective serotonin reuptake inhibitor (SSRI), wherein the SSRI prevents the reduction of serotonin in blood of the individual, and the SSRI is selected from venlafaxine, venlafaxine metabolite, mirtazapine, buspirone |
| 01/31/2002 | US20020013342 Useful for treating a central nervous system disorder selected from depression, mood swings, and Alzheimer's disease |
| 01/31/2002 | US20020013341 For therapy of acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrtate deposition |
| 01/31/2002 | US20020013340 Treatment of ocular disease |
| 01/31/2002 | US20020013339 Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers |
| 01/31/2002 | US20020013337 For therapy of respiratory disorder including adult respiratory distress syndrome (ARDS), bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, rhinitis or chronic sinusitis |
| 01/31/2002 | US20020013336 Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases |
| 01/31/2002 | US20020013335 Method of treating cardiovascular disease |
| 01/31/2002 | US20020013334 HMG-CoA reductase inhibitors and method |
| 01/31/2002 | US20020013333 As inhibitors of matrix metalloproteinase, for therapy of diseases such as degenerative diseases and certain cancers |
| 01/31/2002 | US20020013332 Use of nicergoline for treating spasticity |
| 01/31/2002 | US20020013331 For therapy of pain associated with mucosal damage, such as inflamation, abrasions, ulcerations, lesions, incisions, and trauma |
| 01/31/2002 | US20020013330 Providing sedative-hypnotic treatment by administering barbiturate derivative compound |
| 01/31/2002 | US20020013329 For therapy of pain, migraine, depression, anxiety, schizophrenia, Parkinson's disease, stroke, and in therapy of neuropathies including postherpetic neuralgia, central pain from spinal cord injury, and phantom limb pain |
| 01/31/2002 | US20020013328 For therapy of cancer or other proliferative diseases |
| 01/31/2002 | US20020013327 Administering estrogen agonist/antagonist, and optionally, co-administering an effective amount of a cyclic guanosine 3',5'-monophosphate elevator for therapy of female sexual dysfunction |
| 01/31/2002 | US20020013326 For controlling harmful insects, acarina and nematodes |